Codexis (CDXS) Competitors $2.99 -0.12 (-3.86%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$3.06 +0.07 (+2.51%) As of 07/11/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CDXS vs. GERN, RGLS, MYGN, ZBIO, EBS, RIGL, LXRX, XOMA, CBIO, and VNDAShould you be buying Codexis stock or one of its competitors? The main competitors of Codexis include Geron (GERN), Regulus Therapeutics (RGLS), Myriad Genetics (MYGN), Zenas BioPharma (ZBIO), Emergent Biosolutions (EBS), Rigel Pharmaceuticals (RIGL), Lexicon Pharmaceuticals (LXRX), XOMA Royalty (XOMA), Crescent Biopharma (CBIO), and Vanda Pharmaceuticals (VNDA). These companies are all part of the "biotechnology" industry. Codexis vs. Its Competitors Geron Regulus Therapeutics Myriad Genetics Zenas BioPharma Emergent Biosolutions Rigel Pharmaceuticals Lexicon Pharmaceuticals XOMA Royalty Crescent Biopharma Vanda Pharmaceuticals Geron (NASDAQ:GERN) and Codexis (NASDAQ:CDXS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk and dividends. Which has stronger valuation and earnings, GERN or CDXS? Codexis has lower revenue, but higher earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGeron$76.99M10.92-$174.57M-$0.21-6.29Codexis$59.35M4.17-$65.28M-$0.99-3.02 Do institutionals and insiders have more ownership in GERN or CDXS? 73.7% of Geron shares are owned by institutional investors. Comparatively, 78.5% of Codexis shares are owned by institutional investors. 7.4% of Geron shares are owned by insiders. Comparatively, 2.1% of Codexis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more volatility & risk, GERN or CDXS? Geron has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Comparatively, Codexis has a beta of 2.52, meaning that its stock price is 152% more volatile than the S&P 500. Is GERN or CDXS more profitable? Geron has a net margin of -119.54% compared to Codexis' net margin of -149.47%. Geron's return on equity of -47.86% beat Codexis' return on equity.Company Net Margins Return on Equity Return on Assets Geron-119.54% -47.86% -26.78% Codexis -149.47%-118.47%-53.37% Does the media refer more to GERN or CDXS? In the previous week, Geron had 7 more articles in the media than Codexis. MarketBeat recorded 8 mentions for Geron and 1 mentions for Codexis. Codexis' average media sentiment score of 1.87 beat Geron's score of 0.96 indicating that Codexis is being referred to more favorably in the news media. Company Overall Sentiment Geron Positive Codexis Very Positive Do analysts rate GERN or CDXS? Geron currently has a consensus target price of $4.61, indicating a potential upside of 249.33%. Codexis has a consensus target price of $11.00, indicating a potential upside of 267.89%. Given Codexis' higher possible upside, analysts plainly believe Codexis is more favorable than Geron.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Geron 1 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.60Codexis 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryGeron beats Codexis on 11 of the 17 factors compared between the two stocks. Get Codexis News Delivered to You Automatically Sign up to receive the latest news and ratings for CDXS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CDXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDXS vs. The Competition Export to ExcelMetricCodexisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$257.65M$2.97B$5.62B$9.10BDividend YieldN/A2.39%5.24%4.00%P/E Ratio-3.0220.7128.1020.27Price / Sales4.17292.05429.7098.72Price / CashN/A42.8637.4658.16Price / Book3.657.638.045.49Net Income-$65.28M-$55.05M$3.18B$250.45M7 Day Performance8.33%8.43%3.62%4.78%1 Month Performance32.89%5.42%4.05%7.67%1 Year Performance-6.56%2.03%30.00%16.43% Codexis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDXSCodexis3.4984 of 5 stars$2.99-3.9%$11.00+267.9%-8.3%$257.65M$59.35M-3.02250Positive NewsGERNGeron3.372 of 5 stars$1.37-4.2%$5.06+269.5%-72.3%$910.79M$76.99M-6.5270News CoverageAnalyst ForecastGap DownRGLSRegulus Therapeutics1.5177 of 5 stars$8.16flat$8.50+4.2%N/A$564.92MN/A-11.1830MYGNMyriad Genetics4.6236 of 5 stars$5.29-5.5%$14.38+171.9%-79.4%$516.19M$837.60M-4.722,700News CoveragePositive NewsZBIOZenas BioPharma1.9232 of 5 stars$9.79-2.4%$36.67+274.5%N/A$419.60M$5M-2.76N/AEBSEmergent Biosolutions4.2654 of 5 stars$6.63-5.2%$14.33+116.2%-25.7%$379.40M$1.04B-2.452,420RIGLRigel Pharmaceuticals3.0078 of 5 stars$18.84-0.5%$36.40+93.2%+96.3%$338.33M$179.28M9.10160LXRXLexicon Pharmaceuticals2.6985 of 5 stars$0.87-3.1%$3.67+320.1%-41.9%$325.70M$31.08M-1.71140News CoverageXOMAXOMA Royalty4.0096 of 5 stars$26.17-2.9%$69.50+165.6%+3.7%$322.63M$13.05M-22.7610Positive NewsCBIOCrescent Biopharma3.2669 of 5 stars$15.29-3.8%$25.00+63.5%N/A$310.64M$10K0.0050News CoverageAnalyst UpgradeGap DownHigh Trading VolumeVNDAVanda Pharmaceuticals4.7762 of 5 stars$4.89-1.6%$16.50+237.4%-18.3%$292.90M$198.77M-6.52290 Related Companies and Tools Related Companies GERN Alternatives RGLS Alternatives MYGN Alternatives ZBIO Alternatives EBS Alternatives RIGL Alternatives LXRX Alternatives XOMA Alternatives CBIO Alternatives VNDA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CDXS) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get PaidBank of America believes gold could hit $4,000 an ounce in the next 12 months. That's an 18% jump from toda...Investors Alley | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Codexis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Codexis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
